Objective:To investigate whether stimuli-responsive mesoporous silica nanoparticles(MSNs-SS-HA)as a drug delivery system can improve the targeting and bioavailability of anthraquinone-modified 4S to tri-ple-negative breast cancer(TNBC)cells,while minimizing the toxicity to normal cells.Methods:Functionalized nanoparticles MSNs-SS-HA were prepared by post-modification method,and characterized through transmission electron microscopy,Malvern particle size analyzer,Fourier transform infrared spectroscopy,and elemental analy-sis.In vitro dialysis experiments were performed to detect the release behavior of MSNs@4S and MSNs-SS-HA@4S in different concentrations of glutathione buffer solutions.The inhibitory activity of free 4S and drug-loaded nanoparticles on TNBC cells MDA-MB231,breast cancer cells MCF-7 and normal breast cancer cells MCF-10A was determined by MTT assay.Laser confocal microscopy was used to observe the uptake of anthra-quinone-modified 4S and drug-loaded nanoparticles in different cells.Results:Functionalized drug-loaded nanoparticles MSNs-SS-HA@4S were successfully prepared,with a drug loading capacity and encapsulation effi-ciency of(17.43±1.2)%and(90.56±1.1)%,respectively.The drug-loaded nanoparticles MSNs-SS-HA@4S exhib-it reduction-responsive properties and slow-release drug effects.At the same concentration,the toxicity of MSNs-SS-HA@4S to MDA-MB231 cells was higher than that to MCF-10A cells,but the antitumor activity against MCF-7 cells was weaker(P<0.05).In vitro cellular uptake experiments showed that MSNs-SS-HA@4S was able to target MDA-MB231,a TNBC cell with high expression of CD44,and might enter the cells through CD44 receptor-mediated endocytosis,revealing the potential of MSNs-SS-HA@4S for tumor-targeted therapy.Conclu-sion:MSNs-SS-HA@4S improves the efficacy of anthraquinone modified-4S in potentiation and toxicity reduc-tion,providing new ideas for targeted therapy of TNBC.
关键词
蒽醌修饰物4S/介孔二氧化硅纳米粒/刺激响应性/肿瘤靶向/三阴性乳腺癌
Key words
anthraquinone-modified 4S/mesoporous silica nanoparticles/stimulus responsiveness/tumor target-ing/triple-negative breast cancer